The percentage of IL-22R1+ CD4+ T lymphocytes, both IL-22R+ and IL-22R1++, was mainly higher in severe patients compared to controls, suggesting a possible compensatory mechanism to impaired CD4+ T cell function in COVID-19 patients (52, 55). The gene discussed is CD4; the disease is COVID-19.